The short version of IGF-1 marker fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-08 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
== Taxonomy == The classification of corals has been discussed for millennia, owing to having similarities to both plants and animals. Aristotle's pupil Theophrastus described the red coral, korallion, in his book on stones, implying it was a mineral, but he described it as a deep-sea plant in his Enquiries on Plants, where he also mentions large stony plants that reveal bright flowers when under water in the Gulf of Heroes. Pliny the Elder stated boldly that several sea creatures including sea nettles and sponges "are neither animals nor plants, but are possessed of a third nature (tertia natura)". Petrus Gyllius copied Pliny, introducing the term zoophyta for this third group in his 1535 book On the French and Latin Names of the Fishes of the Marseilles Region; it is popularly but wrongly supposed that Aristotle created the term. Gyllius further noted, following Aristotle, how hard it was to define what was a plant and what was an animal. The Babylonian Talmud refers to coral among a list of types of trees, and the 11th-century French commentator Rashi describes it as "a type of tree (מין עץ) that grows underwater that goes by the (French) name 'coral'." The Persian polymath Al-Biruni (d.1048) classified sponges and corals as animals, arguing that they respond to touch. Nevertheless, people believed corals to be plants until the eighteenth century when William Herschel used a microscope to establish that coral had the characteristic thin cell membranes of an animal.
=== Platelet disorders === Platelet disorders are either congenital or acquired. Examples of congenital platelet disorders are Glanzmann's thrombasthenia, Bernard–Soulier syndrome (abnormal glycoprotein Ib-IX-V complex), gray platelet syndrome (deficient alpha granules), and delta storage pool deficiency (deficient dense granules). Most are rare. They predispose to hemorrhage. Von Willebrand disease is due to deficiency or abnormal function of von Willebrand factor, and leads to a similar bleeding pattern; its milder forms are relatively common. Decreased platelet numbers (thrombocytopenia) is due to insufficient production (e.g., myelodysplastic syndrome or other bone marrow disorders), destruction by the immune system (immune thrombocytopenic purpura), or consumption (e.g., thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, paroxysmal nocturnal hemoglobinuria, disseminated intravascular coagulation, heparin-induced thrombocytopenia). An increase in platelet count is called thrombocytosis, which may lead to formation of thromboembolisms; however, thrombocytosis may be associated with increased risk of either thrombosis or hemorrhage in patients with myeloproliferative neoplasm.
Pseudo means 'false' or 'fake'. The etymology is from the Greek word ψεύδω (pseúdō), which means to lie or deceive. hyper means 'extreme' or 'beyond normal'. The etymology is from the Greek word ὑπέρ (hupér), which means over, above; beyond, to the extreme. trophy means 'nourishment', or 'development'. The etymology is from the Greek word τροφή (trophḗ), which means food, nourishment. The term was used by Duchenne de Boulogne in his description of Duchenne muscular dystrophy in one of his works "paralysie musculaire pseudo-hypertrophique."
Sources: en.wikipedia.org
A single protein binds to two locations of one RNA Two proteins that interact and bind to two locations on one RNA Two proteins are deposited on two locations on one RNA by a coordinated assembly process Using RNP-MaP correlations, a network of protein-RNA interaction sites is found and can then be used for functional analysis.
== Career and research == Williams then spent another period back at Merton, having won a junior research fellowship, Then, “out of the blue, in 1954, Cyril Hinshelwood, then Oxford Professor of Chemistry, asked to see Bob.” He was told that three colleges—Christ Church, Pembroke and Wadham—needed a tutor in chemistry. “Each one will invite you to dine. Come back again in two weeks to give me your decision.” Williams joined Wadham College, Oxford in 1955 and remained there for the rest of his life. His doctoral students include Peter Day, Carole Perry and Michael Thor Pope. William's work in pure inorganic chemistry led to a two-volume textbook of inorganic chemistry, written with Courtenay Phillips, He became increasingly interested in enzyme catalysis, and in particular the role of metal ions, as for example the role of copper in proteins. He and Bert Vallee proposed of the concept of the entatic state whereby atoms and groups in enzyme active sites are maintained by binding to the apoenzyme in positions and states appropriate to catalyse reactions. In the first paper ever published in the Journal of Theoretical Biology Williams argued that spatial separation of the H+ and OH– ions produced in the conversion of ATP to ADP would be necessary for the catalysis. In the same year Peter Mitchell proposed a similar idea in the form of the chemiosmotic hypothesis. In a special issue of the Journal of Theoretical Biology in celebration of 50 years of its existence Williams described the correspondence between Mitchell and himself.
== Production == Ketone bodies are produced mainly in the mitochondria of liver cells, and synthesis can occur in response to an unavailability of blood glucose, such as during fasting. Other cells, e.g. human astrocytes, are capable of carrying out ketogenesis, but they are not as effective at doing so. Ketogenesis occurs constantly in a healthy individual. Ketogenesis in healthy individuals is ultimately under the control of the master regulatory protein AMPK, which is activated during times of metabolic stress, such as carbohydrate insufficiency. Its activation in the liver inhibits lipogenesis, promotes fatty acid oxidation, switches off acetyl-CoA carboxylase, turns on malonyl-CoA decarboxylase, and consequently induces ketogenesis. Ethanol is a potent AMPK inhibitor and therefore can cause significant disruptions in the metabolic state of the liver, including halting of ketogenesis, even in the context of hypoglycemia. Ketogenesis takes place in the setting of low glucose levels in the blood, after exhaustion of other cellular carbohydrate stores, such as glycogen. It can also take place when there is insufficient insulin (e.g. in type 1 (and less commonly type 2) diabetes), particularly during periods of "ketogenic stress" such as intercurrent illness. The production of ketone bodies is then initiated to make available energy that is stored as fatty acids. Fatty acids are enzymatically broken down in β-oxidation to form acetyl-CoA.
Sources: en.wikipedia.org
{\displaystyle {\begin{aligned}\mathbf {J} &=-D{\frac {\partial \rho }{\partial x}}&&{\text{(Fick's law of diffusion)}}\\[5pt]\mathbf {q} &=-k_{t}{\frac {\partial T}{\partial x}}&&{\text{(Fourier's law of heat conduction)}}\\[5pt]\tau &=\mu {\frac {\partial u}{\partial y}}&&{\text{(Newton's law of viscosity)}}\end{aligned}}}
Clostridium scindens is a Gram-positive, obligate anaerobic, pleiomorphic, spore-forming bacterium belonging to the genus Clostridium. C. scindens has been found in humans as a commensal colonizer of the colon. Clostridium scindens is capable of converting primary bile acids to secondary bile acids, as well as converting glucocorticoids to androgens. The presence of C. scindens in the human gut is associated resistance to Clostridioides difficile infection, due to the production of secondary bile acids which inhibit the growth of C. difficile.
Nickel is obtained through extractive metallurgy: it is extracted from ore by conventional roasting and reduction processes that yield metal of greater than 75% purity. In many stainless steel applications, 75% pure nickel can be used without further purification, depending on impurities. Traditionally, most sulfide ores are processed using pyrometallurgical techniques to produce a matte for further refining. Hydrometallurgical techniques are also used. Most sulfide deposits have traditionally been processed by concentration through a froth flotation process followed by pyrometallurgical extraction. The nickel matte is further processed with the Sherritt-Gordon process. First, copper is removed by adding hydrogen sulfide, leaving a concentrate of cobalt and nickel. Then, solvent extraction is used to separate the cobalt and nickel, with the final nickel content greater than 86%. A second common refining process is leaching the metal matte into a nickel salt solution, followed by electrowinning the nickel from solution by plating it onto a cathode as electrolytic nickel.
== Staining procedural notes == Zenker fixative is preferred, although formalin fixed tissue can be used. If this is the case, the tissue should be mordanted in Zenkers solution before staining. Most texts recommend mordanting in Zenker fixative overnight at room temperature, but it can be done for 3.5 hours in a 56 to 60 degrees Celsius oven. PTAH solution, Gram Iodine, 5% sodium thiosulfate, 0.25% Potassium Permanganate, and 5% Oxalic Acid solution are needed. After staining, slides should be dehydrated quickly because the red-brown components lose their color when exposed to water or alcohol.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.